|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
JP4601426B2
(ja)
*
|
2002-09-06 |
2010-12-22 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体成分ｃ５に対する抗体を使用する喘息の処置の方法
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
MXPA05010555A
(es)
|
2003-04-04 |
2006-03-09 |
Genentech Inc |
Formulaciones de proteina y anticuerpo de alta concentracion.
|
|
KR20130065723A
(ko)
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
|
WO2008057459A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
WO2009113083A1
(en)
|
2008-03-14 |
2009-09-17 |
Biocon Limited |
A monoclonal antibody and a method thereof
|
|
BRPI0914916A2
(pt)
|
2008-06-30 |
2015-10-20 |
Novo Nordisk As |
anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
|
|
CN104119438A
(zh)
*
|
2009-01-29 |
2014-10-29 |
米迪缪尼有限公司 |
延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
|
|
AU2010221156A1
(en)
*
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
GB0904214D0
(en)
*
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
EP2427497B1
(fr)
*
|
2009-05-07 |
2016-12-07 |
Stallergenes |
Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
|
|
US8454956B2
(en)
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
EP2501408B1
(en)
*
|
2009-11-20 |
2020-05-27 |
Biocon Limited |
Formulations of antibody
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
DK2533761T3
(da)
|
2010-02-11 |
2019-06-24 |
Ablynx Nv |
Fremgangsmåder og sammensætninger til fremstilling af aerosoler
|
|
EP3409289B1
(en)
*
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
SG10201502398RA
(en)
|
2010-04-27 |
2015-05-28 |
Scil Technology Gmbh |
Stable MIA/CD-RAP formulations
|
|
RU2012153786A
(ru)
*
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
MX2019000046A
(es)
|
2010-11-04 |
2023-10-05 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23.
|
|
RU2578468C2
(ru)
|
2010-12-16 |
2016-03-27 |
Дженентек, Инк. |
Способы диагностики и лечения, связанные с ингибированием th2
|
|
TWI719112B
(zh)
|
2011-03-16 |
2021-02-21 |
賽諾菲公司 |
雙重ｖ區類抗體蛋白質之用途
|
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
SG10201505454SA
(en)
*
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
|
WO2013012022A1
(ja)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
|
ES2936387T3
(es)
|
2011-10-31 |
2023-03-16 |
Hoffmann La Roche |
Formulaciones de anticuerpos anti-il13
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
PL3326649T3
(pl)
*
|
2012-05-03 |
2022-04-25 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23p19
|
|
EA201590061A1
(ru)
*
|
2012-06-21 |
2015-05-29 |
Юсб Фарма С.А. |
Фармацевтическая композиция
|
|
WO2014015133A1
(en)
|
2012-07-19 |
2014-01-23 |
National Cheng Kung University |
Treatment of osteoarthritis using il-20 antagonists
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI679019B
(zh)
*
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
|
|
EP3024485B1
(en)
|
2013-07-23 |
2020-11-18 |
Biocon Limited |
Use of a cd6 binding partner and method based thereon
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
|
CN120904322A
(zh)
|
2013-09-13 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
包含纯化的重组多肽的方法和组合物
|
|
AR098155A1
(es)
|
2013-10-23 |
2016-05-04 |
Genentech Inc |
Métodos para diagnosticar y tratar trastornos eosinofílicos
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
IL310015B2
(en)
|
2013-12-31 |
2026-02-01 |
Access To Advanced Health Inst |
Single vial formulation
|
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
EA202193002A2
(ru)
|
2014-09-03 |
2022-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединение, нацеленное на ил-23a и фно-альфа, и его применение
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
CN107108715A
(zh)
|
2014-10-24 |
2017-08-29 |
默沙东公司 |
胰高血糖素和glp‑1受体的共激动剂
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
WO2016109822A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Novelmed Therapeutics, Inc. |
Formulation of aglycosylated therapeutic antibodies
|
|
AU2016215535B2
(en)
|
2015-02-04 |
2021-09-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
|
MX2017011486A
(es)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
EP3383435A4
(en)
*
|
2015-11-30 |
2019-07-10 |
Medimmune, LLC |
OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
JP6871948B2
(ja)
|
2016-04-27 |
2021-05-19 |
アッヴィ・インコーポレイテッド |
抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
PT3528838T
(pt)
|
2016-09-23 |
2023-09-04 |
Hoffmann La Roche |
Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
|
|
ES2991182T3
(es)
|
2016-10-21 |
2024-12-02 |
Biocon Ltd |
Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
KR20200012823A
(ko)
|
2017-02-01 |
2020-02-05 |
예일 유니버시티 |
이뇨제 내성의 치료
|
|
BR112019018022A2
(pt)
*
|
2017-03-01 |
2020-06-02 |
Medimmune Limited |
Formulações de anticorpos monoclonais
|
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
|
EP3615065A1
(en)
|
2017-04-28 |
2020-03-04 |
Amgen Inc. |
Excipients to reduce the viscosity of antibody formulations and formulation compositions
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
WO2019019998A1
(zh)
*
|
2017-07-25 |
2019-01-31 |
江苏恒瑞医药股份有限公司 |
一种il-15蛋白复合物药物组合物及其用途
|
|
AU2018322475A1
(en)
*
|
2017-08-22 |
2020-03-05 |
Biogen Ma Inc. |
Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
|
|
CN118370815A
(zh)
*
|
2017-08-22 |
2024-07-23 |
渤健马萨诸塞州股份有限公司 |
含有抗β淀粉样蛋白抗体的药物组合物
|
|
EP3735421A4
(en)
|
2018-01-05 |
2021-09-22 |
Corvidia Therapeutics, Inc. |
METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
|
|
US20210223262A1
(en)
*
|
2018-06-07 |
2021-07-22 |
Merck Sharp & Dohme Corp. |
Lyosphere critical reagent kit
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
WO2020092015A1
(en)
|
2018-11-02 |
2020-05-07 |
University Of Rochester |
Therapeutic mitigation of epithelial infection
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
CN120241997A
(zh)
|
2019-02-18 |
2025-07-04 |
伊莱利利公司 |
治疗性抗体制剂
|
|
CN109771398B
(zh)
*
|
2019-02-25 |
2019-09-20 |
广州南鑫药业有限公司 |
一种帕拉米韦溶液型吸入剂及其制备方法
|
|
WO2021034639A1
(en)
*
|
2019-08-16 |
2021-02-25 |
Regeneron Pharmaceuticals, Inc. |
High concentration anti-c5 formulations
|
|
TW202535466A
(zh)
|
2019-09-09 |
2025-09-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-il-23p19抗體調配物
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
JP7730817B6
(ja)
*
|
2019-12-20 |
2025-09-26 |
アレス トレーディング ソシエテ アノニム |
ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
|
|
JP2023512286A
(ja)
*
|
2020-01-31 |
2023-03-24 |
サノフイ |
抗体の肺送達
|
|
IL296276A
(en)
*
|
2020-03-10 |
2022-11-01 |
Tiziana Life Sciences Plc |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
EP4159236A4
(en)
|
2020-05-29 |
2024-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing formulation
|
|
EP4272756A4
(en)
*
|
2021-02-05 |
2024-12-11 |
Bio-Thera Solutions, Ltd. |
ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF
|
|
AU2022345969A1
(en)
|
2021-09-15 |
2024-03-07 |
Dermira, Inc. |
Il-13 inhibitors for the treatment of prurigo nodularis
|
|
CN121002056A
(zh)
|
2023-02-08 |
2025-11-21 |
免疫标记治疗股份公司 |
β2微球蛋白、HLA重链多肽、和CD47–SIRPα抑制剂的融合蛋白
|
|
WO2025128984A1
(en)
|
2023-12-14 |
2025-06-19 |
Dermira, Inc. |
Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
|
|
WO2025128990A1
(en)
|
2023-12-14 |
2025-06-19 |
Dermira, Inc. |
Il-13 antibodies for the treatment of perennial allergic rhinitis
|
|
TW202600591A
(zh)
|
2024-03-01 |
2026-01-01 |
美商德米拉股份有限公司 |
用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
|